

## Appendix Two. International approaches

Table 1: Approaches across jurisdictions to puberty blocker use in treating gender incongruence and dysphoria

Government regulatory intervention	Ban – certain US States, province of Alberta (Canada)
	Ban outside national health system control – UK
	Other regulatory approaches, eg, stipulating consent requirements – Denmark, certain US States
National/State health system controls	Temporary pause in prescribing – State of Queensland, Australia
	Limit use to research settings or high clinical risk – Norway, Sweden, Finland
	Issue Position Statement – NZ
Clinical guidance and professional standards	Many countries including Australia, Japan and most European countries.

PROACTIVELY RELEASED